요네병 진단 시장 예측(2026-2032년)

The Johne's Disease Diagnostics Market is projected to grow by USD 1,164.11 million at a CAGR of 7.45% by 2032.

Johne's disease diagnostics are becoming central to livestock health management as dairy and beef producers, veterinarians, laboratories, and animal health authorities work to control Mycobacterium avium subspecies paratuberculosis (MAP), the causative agent of Johne's disease, also known as paratuberculosis. The disease is chronic, progressive, and difficult to eradicate once established in a herd, making early detection, risk-based surveillance, and long-term herd management essential. Diagnostic workflows commonly combine enzyme-linked immunosorbent assay (ELISA), fecal culture, polymerase chain reaction (PCR), environmental sampling, and confirmatory testing to identify infected animals and reduce transmission through manure, colostrum, milk, and contaminated calving environments. Demand for reliable Johne's disease testing is supported by the documented economic burden of reduced milk production, premature culling, lower fertility performance, and compromised animal welfare. Because MAP infection may remain subclinical for years, diagnostics must balance sensitivity, specificity, sampling frequency, herd prevalence, and stage of infection. The strongest diagnostic strategies are therefore not isolated tests but integrated testing programs that combine laboratory evidence with biosecurity, calf management, manure control, risk classification, and veterinary interpretation. As food supply chains place greater emphasis on traceability, antimicrobial stewardship, animal welfare, and preventive herd health, Johne's disease diagnostics are evolving from reactive disease confirmation toward proactive herd-level control and assurance.

Transformative Shifts in the Johne's Disease Diagnostics Landscape

The Johne's disease diagnostics landscape is shifting from occasional animal-level testing toward continuous, data-informed herd surveillance. Traditional fecal culture remains valued for specificity but is slow because MAP is a slow-growing organism, while PCR offers faster detection of MAP DNA and supports more timely decisions on isolation, culling, or management segregation. ELISA continues to play a major role in herd screening due to scalability and practicality, especially when interpreted alongside clinical history and repeated testing. Environmental sampling is gaining relevance for detecting herd-level shedding patterns, particularly in large dairy operations where individual animal sampling can be resource intensive. A major transformation is the movement toward risk-based testing protocols that prioritize high-risk age groups, clinical suspects, purchased animals, and herds with known transmission pathways. Laboratories are also improving sample logistics, digital reporting, quality assurance, and decision-support outputs to help veterinarians translate results into actionable control plans. Another important shift is the growing alignment of diagnostics with farm certification, voluntary control programs, and regional surveillance frameworks. As producers seek to reduce chronic disease losses and improve herd resilience, Johne's disease testing is becoming an embedded component of preventive veterinary services rather than a one-time diagnostic event.

Cumulative Impact of Artificial Intelligence on Johne's Disease Testing

Artificial intelligence is beginning to influence Johne's disease diagnostics by improving how complex herd data are interpreted rather than by replacing established laboratory methods. AI-enabled analytics can combine longitudinal ELISA results, PCR outcomes, milk production records, parity, age, calving history, animal movement data, and clinical observations to flag animals or groups that warrant retesting or management intervention. Machine learning models can support risk stratification in herds where MAP infection is intermittent, subclinical, and difficult to detect through a single diagnostic event. In laboratory operations, AI can assist with workflow optimization, anomaly detection in test results, image or signal interpretation where applicable, and automated quality-control review. For veterinarians and producers, decision-support tools can translate diagnostic data into practical recommendations, such as prioritizing calf management changes, identifying high-risk pens, or refining testing intervals. The cumulative impact of artificial intelligence will be strongest when models are trained on validated datasets, governed by transparent performance metrics, and integrated with veterinary oversight. Given the biological complexity of MAP infection and the consequences of false-positive or false-negative interpretation, AI should be viewed as an augmentation layer that enhances surveillance precision, not as a standalone diagnostic authority.

Key Regional Insights for Johne's Disease Diagnostics

In Asia-Pacific, Johne's disease diagnostics are shaped by rapidly modernizing dairy systems, mixed herd structures, and the need to strengthen laboratory capacity across diverse production environments. Countries with intensive dairy and beef operations are increasingly emphasizing PCR, ELISA, and herd-level screening to support biosecurity and productivity, while smallholder-dominant areas require cost-effective sampling strategies and stronger veterinary outreach. Europe maintains a strong focus on animal welfare, food chain assurance, and coordinated disease control, with many countries using herd classification, targeted testing, and veterinary-supervised control strategies. The European diagnostic landscape is also influenced by stringent laboratory standards, traceability requirements, and cross-border livestock trade considerations. North America has one of the most developed diagnostic ecosystems for Johne's disease, supported by established veterinary laboratory networks, voluntary herd control programs, dairy herd health consulting, and wide use of ELISA, fecal PCR, and environmental testing. The region's emphasis on preventive herd health, milk quality, and traceable livestock movement supports structured MAP surveillance. Latin America presents a varied diagnostic environment, with Brazil and Mexico contributing significant demand due to large cattle populations and expanding dairy and beef production. Adoption is closely tied to veterinary service access, producer awareness, and the ability to integrate MAP testing with broader infectious disease control. Africa faces a more fragmented diagnostic landscape, with demand linked to dairy development programs, imported cattle genetics, and the need to improve surveillance for chronic livestock diseases. Regional progress depends on laboratory infrastructure, affordability, sample transport systems, and integration of Johne's disease diagnostics into broader veterinary public and production health programs. In the Middle East, Johne's disease diagnostics are gaining attention where dairy intensification, imported breeding stock, and high-value herd investments increase the importance of biosecurity screening. Testing adoption is often concentrated in commercial farms and government-supported animal health initiatives.

Key Group Insights for Johne's Disease Diagnostics

Across NATO member countries, many of which overlap with advanced livestock economies in North America and Europe, Johne's disease diagnostics benefit from robust biosecurity cultures, coordinated veterinary systems, and established diagnostic laboratory networks. G7 countries generally demonstrate advanced diagnostic capacity, strong laboratory accreditation practices, and widespread access to veterinary expertise, enabling sophisticated surveillance models that combine serology, molecular testing, environmental sampling, and herd-level risk assessment. BRICS economies bring together some of the world's largest livestock populations and diverse production systems, making Johne's disease diagnostics relevant for productivity protection, genetic improvement programs, and long-term herd resilience. In these countries, diagnostic adoption is strongly connected to scalable testing models, veterinary infrastructure, and modernization of dairy and beef value chains. The European Union supports a more structured environment for MAP diagnostics through harmonized animal health principles, quality-controlled laboratories, and strong emphasis on animal welfare and food system transparency. EU-level trade integration also increases the importance of reliable testing documentation across borders. Within ASEAN, Johne's disease diagnostics are influenced by the coexistence of smallholder dairy farms, commercial livestock operations, and expanding veterinary laboratory networks. Practical testing strategies in the group tend to prioritize affordable screening, producer education, and integration with broader herd health programs. In the GCC, high-value dairy systems, climate-controlled production units, and dependence on imported genetics make disease prevention and entry screening important drivers of Johne's disease testing, particularly where herd biosecurity is a strategic priority. Across these groups, the common trend is the movement from isolated testing toward integrated MAP control programs that connect diagnostics with animal movement controls, calf hygiene, manure management, and producer decision support.

Key Country Insights for Johne's Disease Diagnostics

China is strengthening animal health diagnostics as livestock systems industrialize, with Johne's disease testing becoming more relevant in large dairy operations, herd expansion programs, and imported genetics management. The United States has a mature Johne's disease diagnostics environment supported by extensive veterinary laboratory access, dairy herd health programs, and common use of ELISA, fecal PCR, and environmental sampling in risk-based control plans. Japan is characterized by high biosecurity expectations, advanced laboratory systems, and intensive livestock management, supporting precise diagnostic use in herd health programs. India, with one of the world's largest cattle and buffalo populations, faces a complex diagnostic challenge due to diverse farm sizes, regional veterinary capacity differences, and the need for scalable, affordable screening. Germany combines advanced laboratory capacity with a strong dairy tradition, where diagnostics are increasingly aligned with animal welfare, farm assurance, and biosecurity programs. The United Kingdom emphasizes veterinary-led disease control, quality assurance, and herd health planning, making Johne's disease testing an important tool in dairy management. Australia benefits from a strong veterinary surveillance culture, export-oriented livestock standards, and established biosecurity practices, making Johne's disease diagnostics part of a broader framework for disease risk management and herd assurance. France, Italy, and Spain combine developed laboratory infrastructure with significant dairy and ruminant production, where MAP testing supports herd classification, animal welfare objectives, and preventive veterinary services. South Korea's intensive livestock systems, high traceability expectations, and advanced laboratory capabilities support targeted use of Johne's disease diagnostics in biosecurity-focused herd health programs. Canada shows strong veterinary oversight, producer education, and attention to herd biosecurity in dairy and beef systems, with diagnostic use supported by laboratory access and disease control awareness. Russia's broad geography and mixed production systems create uneven diagnostic access, but large-scale dairy modernization supports demand for structured disease monitoring. Brazil's large dairy and beef industries create significant relevance for MAP surveillance, particularly in commercial herds seeking to improve reproductive performance, milk output, and herd longevity. Mexico's diagnostic adoption is supported by its large cattle sector and growing emphasis on productivity, although access to advanced testing can vary by region and production scale.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize integrated diagnostic programs that combine ELISA, PCR, environmental sampling, and veterinary risk assessment rather than relying on a single test result. Diagnostic providers and laboratories should strengthen assay validation, turnaround time, sample traceability, digital reporting, and interpretive guidance to help producers make timely herd management decisions. Veterinary service organizations should expand producer education on MAP transmission, especially calf exposure, manure contamination, colostrum management, and risks linked to purchasing replacement animals. Livestock operators should implement repeat testing strategies, segregate high-risk animals, improve maternity pen hygiene, avoid feeding pooled colostrum from unverified cows, and align culling decisions with veterinary interpretation. Policymakers and animal health authorities can improve outcomes by supporting voluntary control programs, laboratory quality standards, surveillance coordination, and accessible testing for small and medium-sized farms. Technology developers should focus on decision-support platforms that integrate diagnostic results with farm records while maintaining transparency, data security, and veterinary accountability. Across the value chain, the most effective strategy is to treat Johne's disease diagnostics as part of a continuous control system that links testing frequency, biosecurity, animal movement, and long-term herd improvement.

Research Methodology

This executive summary is developed through a structured secondary research methodology focused on verified veterinary, animal health, diagnostic, and livestock management sources. The approach includes review of peer-reviewed scientific literature on Mycobacterium avium subspecies paratuberculosis, diagnostic test performance, MAP transmission, and herd control strategies. It also considers publicly available guidance from veterinary authorities, agricultural extension programs, animal health organizations, laboratory best-practice references, and disease control frameworks. Insights are synthesized across diagnostic modalities, including ELISA, fecal culture, PCR, environmental sampling, and herd-level surveillance models. Regional, group, and country perspectives are derived from documented differences in livestock production systems, veterinary infrastructure, laboratory capacity, biosecurity practices, and animal health governance. The methodology excludes market sizing, forecasting, and competitive share analysis, focusing instead on evidence-backed industry dynamics, adoption drivers, operational challenges, and practical implications for stakeholders. Content is validated for consistency with established knowledge that Johne's disease is chronic, often subclinical, difficult to eradicate, and best managed through repeated testing combined with biosecurity and herd management controls.

Conclusion

Johne's disease diagnostics are entering a more strategic phase as livestock industries move toward preventive health management, traceability, and data-driven biosecurity. Because MAP infection can remain hidden for long periods and spread through herd environments before clinical signs appear, diagnostic value depends on repeated surveillance, correct test selection, and veterinary interpretation. ELISA, PCR, culture, and environmental sampling each play distinct roles, and the most resilient control programs use these tools in combination with calf hygiene, manure management, animal movement controls, and producer education. Regional adoption varies according to laboratory capacity, herd structure, commercial intensity, and policy support, but the global direction is clear: Johne's disease testing is becoming more integrated, digital, and risk based. Artificial intelligence and advanced analytics can further strengthen surveillance when paired with validated laboratory results and accountable veterinary decision-making. For industry leaders, the opportunity lies in building accessible, reliable, and actionable diagnostic ecosystems that reduce chronic disease losses, improve animal welfare, and support sustainable livestock productivity without overreliance on one-time testing or unverified assumptions.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Johne's Disease Diagnostics Market, by Animal Type

• 7.1. Introduction
• 7.2. Cattle
  • 7.2.1. Beef Cattle
  • 7.2.2. Dairy Cattle
• 7.3. Sheep & Goats

8. Johne's Disease Diagnostics Market, by Test Type

• 8.1. Introduction
• 8.2. Culture
  • 8.2.1. Liquid Media Culture
  • 8.2.2. Solid Media Culture
• 8.3. ELISA
• 8.4. PCR
• 8.5. Sequencing-Based Assays
  • 8.5.1. Targeted Sequencing Panels
  • 8.5.2. Whole-Genome Sequencing

9. Johne's Disease Diagnostics Market, by Sample Type

• 9.1. Introduction
• 9.2. Fecal Samples
• 9.3. Milk Samples
• 9.4. Tissue Samples

10. Johne's Disease Diagnostics Market, by End User

• 10.1. Introduction
• 10.2. Diagnostic Labs
  • 10.2.1. Hospital Labs
  • 10.2.2. Independent Labs
• 10.3. Farms
  • 10.3.1. Breeding Farms
  • 10.3.2. Dairy Farms
• 10.4. Research Institutes
• 10.5. Veterinary Clinics

11. Johne's Disease Diagnostics Market, by Distribution Channel

• 11.1. Introduction
• 11.2. Offline
• 11.3. Online

12. Johne's Disease Diagnostics Market, by Region

• 12.1. Asia-Pacific
• 12.2. Europe
• 12.3. North America
• 12.4. Latin America
• 12.5. Africa
• 12.6. Middle East

13. Johne's Disease Diagnostics Market, by Group

• 13.1. NATO
• 13.2. G7
• 13.3. BRICS
• 13.4. European Union
• 13.5. ASEAN
• 13.6. GCC

14. Johne's Disease Diagnostics Market, by Country

• 14.1. China
• 14.2. United States
• 14.3. Japan
• 14.4. India
• 14.5. Germany
• 14.6. United Kingdom
• 14.7. Australia
• 14.8. France
• 14.9. South Korea
• 14.10. Italy
• 14.11. Canada
• 14.12. Russia
• 14.13. Brazil
• 14.14. Mexico
• 14.15. Spain

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. FPNV Positioning Matrix, 2025
• 15.3. Market Concentration Analysis, 2025
  • 15.3.1. Concentration Ratio (CR)
  • 15.3.2. Herfindahl Hirschman Index (HHI)
• 15.4. Recent Developments & Impact Analysis, 2025
• 15.5. Product Portfolio Analysis, 2025
• 15.6. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Abcam plc
• 16.2. Agrolabo S.p.A.
• 16.3. BBI Solutions OEM Ltd.
• 16.4. Bio-Rad Laboratories, Inc.
• 16.5. bioMerieux SA
• 16.6. BioNote, Inc.
• 16.7. Biopanda Reagents Ltd.
• 16.8. Cusabio Technology LLC
• 16.9. DNA Diagnostic A/S
• 16.10. Enzo Biochem, Inc.
• 16.11. FineTest Biotech Co., Ltd.
• 16.12. Gold Standard Diagnostics Budapest Kft.
• 16.13. HiMedia Laboratories Pvt. Ltd.
• 16.14. IDEXX Laboratories, Inc.
• 16.15. INDICAL BIOSCIENCE GmbH
• 16.16. Innovative Diagnostics SAS
• 16.17. LGC Clinical Diagnostics, Inc.
• 16.18. MV Diagnostics Ltd.
• 16.19. MyBioSource, Inc.
• 16.20. Neogen Corporation
• 16.21. PBD Biotech Ltd.
• 16.22. Pictor Diagnostics Ltd.
• 16.23. Promega Corporation
• 16.24. QIAGEN N.V.
• 16.25. Randox Laboratories Ltd.
• 16.26. RayBiotech, Inc.
• 16.27. Tetracore, Inc.
• 16.28. Thermo Fisher Scientific Inc.
• 16.29. VMRD, Inc.
• 16.30. Zoetis Inc.